Association Between FEV₁ Decline Rate and Mortality in Long-Term Follow-Up of a 21-Patient Pilot Clinical Trial of Inhaled Liposomal Cyclosporine Plus Standard-of-Care Versus Standard-of-Care Alone for Bronchiolitis Obliterans Syndrome After Lung Transplantation

14 May 2024 : Original article

Aldo Iacono^1ABDEF*, Marniker Wijesinha

^2DE, Andreas Völp

^3CD, Maksim Korotun^1D, Michael Terrin^2AD

DOI: 10.12659/AOT.942823

Ann Transplant 2024; 29:e942823

Introduction Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 2 Associations of key variables with overall mortality, in Cox regression model.

	Hazard ratio	95% CI		p-value
	Hazard ratio	Lower	Upper	p-value
Treatment: L-CsA-I (vs SOC)	0.437	0.136	1.404	0.164
Type of lung transplant: double (vs single)	0.629	0.140	2.823	0.545
Sex: Female (vs Male)	0.520	0.145	1.866	0.316
Age (per year)	1.025	0.967	1.086	0.413
FEV1 at baseline (per Liter)	1.155	0.375	3.558	0.801
BOS grade at screening: 2 (vs 1)	2.747	0.722	10.456	0.138
L-CsA-I – inhaled liposomal cyclosporine A; SOC – standard of care; BOS – bronchiolitis obliterans syndrome; FEV – forced expiratory volume in 1 second.

Back to the Article